Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. announced that all resolutions proposed at its 2024 Annual General Meeting (AGM) were approved. The AGM, held on June 27, 2025, included the election of a new chairman and board members, re-appointment of auditors, and approval of the 2024 annual report and profit distribution plan. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued governance and operational stability.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. It focuses on the development and commercialization of transcatheter heart valve products and related services.
Average Trading Volume: 3,177,973
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.16B
Learn more about 2500 stock on TipRanks’ Stock Analysis page.